Tag Archives: obesity

The next big obesity medication coming down the pipeline will likely come in pill form. Eli Lilly has just released the latest positive Phase III trial results of its experimental oral GLP-1 drug, orforglipron. On Tuesday morning, Eli Lilly reported that orforglipron met the benchmarks of the company’s Phase III ATTAIN-2 study. People taking orforglipron experienced substantial improvements in weight …

Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals  The Wall Street Journal Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval  CNBC Eli Lilly Says New Pill Results in 10.5% Weight-Loss for Diabetes Patients. The Stock Is Up.  Barron’s Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory …

Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity  Eli Lilly and Company Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval  CNBC Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals  The Wall Street Journal Eli Lilly’s weight-loss pill meets …

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. In a key late-stage trial, Eli Lilly’s pill, orforglipron, caused …

Investing.com — Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) shares gained 1.5% as analysts pointed to competitive advantages. The trial demonstrated that Viking’s oral tablet formulation of VK2735, a dual GLP-1 and GIP receptor agonist, met its primary …

Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for Placebo Exploratory Assessment of Low Dose Maintenance Treatment Demonstrates Positive Proof of Concept VK2735 Shown to be Safe …

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators on Friday to treat an increasingly common liver disease, adding to the list of conditions for which the blockbuster therapy is now approved.  The Food and Drug Administration granted accelerated approval to Wegovy for patients with metabolic dysfunction-associated steatohepatitis, or MASH, with moderate to advanced liver scarring. The decision was …

Could This Tiny Molecule Be Better Than Ozempic and Wegovy for Obesity?  SciTechDaily Scientists just found a tiny molecule that could change how we lose weight  ScienceDaily Researchers Identify Microproteins as Potential Tools for Addressing Obesity Affecting Over One Billion Worldwide  geneonline.com Hidden Proteins in Fat May Unlock Obesity Cure  ScienceBlog.com Discovering Microproteins as Novel Therapies for Obesity and Metabolic Disorders  BIOENGINEER.ORG Source link

Eli Lilly delivered strong second-quarter results on Thursday, but shares are plummeting because of disappointing data for a key late-stage trial. It’s forcing us to ask ourselves difficult questions about this once-loved stock. Revenue in the three months ended June 30 jumped 38% year over year to $15.56 billion, beating Wall Street expectations of $14.71 billion, according to LSEG. Adjusted …

Lilly’s oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity  Eli Lilly and Company Eli Lilly’s obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for approval  CNBC Lilly’s Obesity Pill Cut Body Weight by 11% in Key …